

Global Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

<https://marketpublishers.com/r/GA398E909C4EN.html>

Date: August 2019

Pages: 112

Price: US\$ 1,799.00 (Single User License)

ID: GA398E909C4EN

Abstracts

High levels of pipeline activity are being observed in Post-Traumatic Stress Disorder (PTSD) treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including Actinogen Medical Ltd , Addex Therapeutics Ltd, Amorsa Therapeutics Inc, Anagin Inc, Aptinyx Inc and others.

A Significant contribution to the Post-Traumatic Stress Disorder (PTSD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Post-Traumatic Stress Disorder (PTSD) pipeline included 30 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Post-Traumatic Stress Disorder (PTSD) condition and increased access to investments is encouraging growth of Post-Traumatic Stress Disorder (PTSD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Post-Traumatic Stress Disorder (PTSD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Post-Traumatic Stress Disorder (PTSD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Post-Traumatic Stress Disorder (PTSD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Post-Traumatic Stress Disorder (PTSD). Further, orphan drug status, fast track designation, grants awarded and other special status for Post-Traumatic Stress Disorder (PTSD) pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Post-Traumatic Stress Disorder (PTSD) pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Post-Traumatic Stress Disorder (PTSD) Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Post-Traumatic Stress Disorder (PTSD) drugs

Late phase: Phase 3 and in-approval Post-Traumatic Stress Disorder (PTSD) drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Post-Traumatic Stress Disorder (PTSD) therapeutic treatment activities

Details for each Post-Traumatic Stress Disorder (PTSD) drug candidate-

Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Post-Traumatic Stress Disorder (PTSD) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Post-Traumatic Stress Disorder (PTSD)- Disease Overview
- 2.2 Post-Traumatic Stress Disorder (PTSD)- Pipeline Snapshot
- 2.3 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Phase
- 2.4 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Company
- 2.5 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Actinogen Medical Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2-2019
- 3.2 Addex Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2-2019
- 3.3 Amorsa Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.4 Anagin Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.5 Aptinyx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.6 Armgo Pharma Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.7 Artelo Biosciences Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2-2019
- 3.8 Azevan Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.9 Catalyst Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.10 Chronos Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.11 Corcept Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.12 Eli Lilly and Co Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.13 Embera NeuroTherapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019

- 3.14 EpiVario Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.15 HMNC Brain Health Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.16 HydRx Farms Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.17 Immodulon Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.18 Johnson & Johnson Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.19 Kdac Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.20 Lixte Biotechnology Holdings Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.21 NeuroNascent Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.22 NeuroRx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.23 Neurovation Labs Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.24 Omeros Corporation Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.25 One World Cannabis Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.26 Otsuka Holdings Co Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.27 Quoin Pharmaceuticals Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.28 Seelos Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.29 SpringWorks Therapeutics LLC Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
- 3.30 Tonix Pharmaceuticals Holding Corp Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Details
- 4.2 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Overview
- 4.3 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Details
- 5.2 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Overview
- 5.3 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Details
- 6.2 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Overview
- 6.3 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Details
- 7.2 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Overview
- 7.3 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology

I would like to order

Product name: Global Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/GA398E909C4EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA398E909C4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

